Cytena GmbH, a Freiburg, Germany-based life science startup, completed €3m Series A funding.
Backers included two private investors and High-Tech Gründerfonds (HTGF).
The company intends to use the funds to continue developing its single-cell printer lab technology, expand sales activities, and open up further applications for its single-cell printers.
Founded in 2014 as a spin-off from the Institute for Microsystems Technology (IMTEK) at the University of Freiburg, Cytena primarily sells solutions for handling biological cells. The team has developed patented single-cell printer™ technology, which allows the isolation of single cells in a documented, gentle and sterile process. Single-cell printers have been manufactured in Germany and marketed worldwide since 2015.
In 2018, the x.sight™ series was added to the product portfolio.
FinSMEs
26/03/2019